INTRODUCTION

Impairment of immunologic defenses in patients with
Down's syndrome can be inferred from a number of clinical and epidemiological studies. Several authors have reported increased susceptibility of these patients to infections, particularly those of the respiratory tract (1) (2) (3) . Institutionalized patients with Down's syndrome also have a high frequency of Australia antigen associated with chronic anicteric hepatitis (4) . Furthermore, these patients have been shown to have a high prevalence of thyroid autoantibodies (5, 6 ) and a much higher risk of developing leukemia than those in the general population (7, 8) . It is possible that defects in the immune shield may not only make these patients vulnerable to infectious agents but to allergens and carcinogens as well. Although there is evidence of immune deficiencies in patients with solid tissue tumors and leukemia, there is no direct evidence that abnormal immune responsiveness precedes the development of these malignancies (9, 10) . The high susceptibility of patients with Down's syndrome to leukemia is of particular significance, since it provides an opportunity to study immunological functions before the onset of clinical leukemia in a well defined group. The in vitro lymphocyte stimulation test has been used by several workers to evaluate cellular immunity (11, 12) . The ability of lymphocytes to respond to a mitogen is commonly measured by observing the morphological transformation of these cells into large blast-like cells (blastogenesis) and by measuring the amount of radioactive thymidine incorporated into cellular DNA by these cells. We recently reported that addition of phytohemagglutinin (PHA) to cultures of human peripheral lymphocytes results in a 30-to 100-fold increase in DNA polymerase activity and that it could be a more reliable parameter of mitogenic response (13) . In the present study we have examined the utility of this parameter along with the measurement of radioactive thymidine incorporation and cytological observations to monitor the lymphocyte stimulation. Results from the patients with Down's syndrome are compared with those from other mentally retarded patients without Down's syndrome and from normal controls. The findings are discussed in relation to the presence of Australia antigen in patients with Down's syndrome, other immunological functions and genetic constitution of these patients.
The Journal of Clinical Investigation Volume 49 1970METHODS Selection of patients. The studies were carried out on lymphocytes from 12 patients with Down's syndrome (2 females, 10 males) from Pennhurst State School and Hospital, Spring City, Pa. Six of these patients had Australia antigen in their peripheral blood, and six did not. The diagnosis of Down's syndrome was confirmed by karyotype analysis; all the patients had trisomy of the G group. Simultaneously, studies were done on lymphocytes from six mentally retarded children without Down's syndrome from the same institution (one female, five males) and six normal healthy volunteers from our staff. All six mentally retarded patients without Down's syndrome were karyotypically normal. Written permission was obtained from the parents of all mentally retarded patients for these studies. All persons were carefully age and sex matched. The age range of patients with Down's syndrome was between 14 and 22 yr, with a mean of 17.6 yr. The ages of other mentally retarded patients without Down's syndrome ranged from 16 to 18 yr, with a mean of 17.1 yr; the normal controls were between 18 and 22 yr of age.
In (14) . The final preparation of lymphocytes was suspended at a concentration of 7.5 X 10' cells/ml in Eagle's MEM (Spinner modification) (GIBCO, Grand Island, N. Y.), with 20% fetal calf serum, 1%o 1-glutamine, penicillin (100 U/ml), and streptomycin (100 ,g/ml). 2 (16) . The extent of blast transformation and mitosis was determined by adding 0.1 ml of Velban 2 (0.5 ttg/ml) to designated 2 ml cultures. 2 hr later the cells were fixed in acetic-methanol (1: 3) and airdried preparations (17) were stained with Giemsa. From each culture, a total of 1000 cells were counted and grouped into small lymphocytes, lymphoblasts, and cells in mitosis.
RESULTS
The study was statistically evaluated with the use of Wilcoxon's matched-pairs signed-ranks test (18) . The total study included six age-and sex-matched quartets. Each quartet consisted of a patient with Down's syndrome with Australia antigen, a patient with Down's syndrome without Australia antigen, a mentally retarded patient without Down's syndrome from the same institution, and a normal healthy volunteer. The lymphocytes from each patient were cultured in triplicate in the presence of PHA. Determinations of DNA polymerase activity and thymidine uptake in the triplicate assays were in fair agreement (±+10%). The experiment on each quartet was repeated at least once on another day in order to test whether the differences were in the same direction. The results of each quartet were sequentially analyzed (19) to decide when to stop the study.
Optimum concentration of PHA. The lymphocytes from a quartet were cultured with different concentrations of PHA. The response of a normal healthy volunteer and a patient with Down's syndrome, as a function of the amount of PHA added to the culture, is shown in Table I . The amount of PHA routinely used is designated as 1 X which corresponds to 50 Ag/1.5 X 106 lymphocytes in a 2 ml culture. The response to 1 X and 2 X concentrations is essentially the same both in the normal individual and in the patient with Down's syndrome, except that the DNA polymerase activity is higher with 1 X concentration in cultures from the normal person. In contrast, the lower concentrations (1: 10 and 1: 25) and the higher concentration (5 X) evoked significantly lower responses than those obtained with 1 X concentration. There was no detectable response to 1: 100 and 1: 50 concentrations of PHA in all four members of the quartet. We did not find any differences in the from patients with Down's syndrome and from the normal controls (see Table IV ).
Comparison with other mentally retarded children. In order to evaluate the possible contribution of host and environmental factors on the extent of lymphocyte stimulation in patients with Down's syndrome, age-and sex-matched mentally retarded patients without Down's syndrome from the same institution were included in each experimental quartet. Results of the DNA polymerase activity are shown in Table II (compare columns  3 and 4 with column 2) and the extent of thymidine incorporation is shown in Table III (compare columns 3 and 4 with column 2). There is significantly lower DNA polymerase activity (P < 0.001) and thymidine incorporation (P < 0.001) in cultures from patients with Down's syndrome than in cultures from mentally retarded patients without Down's syndrome. Sequential analysis of the results is shown in Fig. 2 This shows that the institutionalization per se is not responsible for the differences in lymphocyte stimulation as seen in patients with Down's syndrome (Fig. 2 b) .
Australia antigen and patients with Down's syndrome. The association of Australia antigen with hepatitis (20) and its persistence in some patients with Down's syndrome can be used to study the possible relationship between lymphocyte stimulation and the presence of chronic hepatitis. When the level of DNA polymerase activity and the uptake of thymidine are considered in Normals (A) compared with patients with Down's syndrome (B)
Mentally retarded patients without Down's syndrome (A) compared with patients with Down's syndrome (B) relation to the presence or absence of Australia antigen in patients with Down's syndrome (compare columns  3 and 4 in Tables II and III) , we do not find any significant differences. P values for both, by Wilcoxon's matched-pairs signed-ranks test, are > 0.05. The data are insufficient for a definite answer by sequential analysis but the trend suggests that there is no difference between the two groups (Fig. 2 d) .
Relationship of lymphocyte stimulation to immunoglobulin levels. Total Patients with Down's syndrome having Australia antigen (A) compared with patients with Down's syndrome without Australia antigen (B) FIGURE 2. Results of sequential analysis based on pair differences (19) .
Significance probability a= 0.05. Lymphocytes from both the members of the pair (designated A and B as above) were cultured in presence of PHA simultaneously and assayed for DNA polymerase activity. If the activity in A was higher than B, a cross was made immediately above the black square in the chart. If the activity in B was higher than A, a cross was made in the square immediately to the right of the black square. If there is no difference, no entry is made. A second test was made in exactly the same way and the result was entered in the square above or to the right of that marked in the first test and so on for successive tests. Results of repeat experiments on the same group are also plotted separately each time. As soon as the barrier is overstepped one of the following decisions is indicated: (1) upper barrier (U) overstepped, response in A is higher than in B; (2) lower barrier (L) overstepped, response in B is higher than in A; (3) Skin tests. Delayed cutaneous hypersensitivity was tested for the antigens listed in the methods section. 6 of the 12 patients with Down's syndrome did not react to any of the antigens while only one of the five mentally retarded patients without Down's syndrome did not react. There was no distinct pattern of reactivity to different antigens in the two groups. As most patients reacted to one or two antigens only, our data are not sufficient to determine the correlation between skin reactivity and lymphocyte stimulation.
Results of studies on other patients. In one patient with Down's syndrome with D/G translocation the response to PHA stimulation was significantly lower than that in the normal control. These findings are similar to those seen in other trisomic mongols. The mother of this patient is the carrier of the trait and she had a similarly low response whereas the response in the father was normal (Table VII However, the rate of thymidine incorporation may be subject to fluctuations in the concentrations of metabolites within the cell as well as by the activities of the enzymes on the "salvage pathway" by which the external thymidine is incorporated into cellular DNA. In this regard a simultaneous assay of the DNA polymerase activity on the same cultures may not only provide a confirmatory evidence for the validity of thymidine uptake results but may also provide a more reliable parameter to evaluate the true mitogenic response. The addition of PHA to cultures of human lymphocytes results in a marked increase in DNA polymerase activity which is closely related temporally and in magnitude to thymidine incorporation into cellular DNA by the same cultures (13) . The activity of the enzyme is assayed in vitro using the cell lysate and known concentrations of substrates. The sensitivity of the assay is only limited by the specific activity of the radioactive precursor. Further the two parameters are independent measurements of the ability of the cells to synthesize DNA. In the present study the DNA polymerase activity and thymidine uptake measurements run parallel in all the lymphocyte cultures from patients with Down's syndrome. Thus the lymphocytes from patients with Down's syndrome are truly hyporesponsive to the mitogenic stimulus of PHA. This disparity between the morphological changes and biochemical events following the PHA stimulation of lymphocytes from patients with Down's syndrome may explain the differences in our results from those reported by Hayakawa, Matsui, Higurashi, and Kabayashi (22) and Sasaki and Obara (23) .
The immune status of patients with Down's syndrome has not been systematically studied. Donner (2) found a significantly lower number of tuberculin-positive individuals among patients with Down's syndrome compared with other children from the same locales. However, vaccination with Calmette-Guerin bacillus (BCG) evoked a similar response in patients with Down's syndrome and normal controls. Impairment of antibody formation and functions has not been conclusively demonstrated. The total amount of gamma globulin appears to be increased (24, 25 (27, 28) . In view of the uncertainties about defects in the humoral antibody in patients with Down's syndrome, the impairment of lymphocyte stimulation could be particularly germane to the clinical observations.
The essential role of circulating lymphocytes in immune responses is well documented (29) . PHA-induced in vitro lymphocyte stimulation has been used to assess the immune capabilities of these cells (11, 12, 30, 31) . When lymphocytes are cultured in the presence of PHA there is a sequential stimulation of RNA, protein, and DNA synthesis. Simultaneously these cells also undergo morphologic changes resulting in large cells with prominent nucleoli and intensely basophilic cytoplasm. Cells of similar appearance are observed in the regional lymph nodes after in vivo immunization (32) . Changes similar to those that occur on PHA stimulation are observed on stimulating lymphocytes with antigens to which a person is known to have been sensitized previously (33, 34) and in mixed leukocyte reactions where histocompatibility antigens appear to be the stimulating factors (14) . PHA-treated lymphocytes have been shOwn to synthesize immunoglobulins (35) (36) (37) , specific antibodies (36, 37) , and interferon (38) . PHA-stimulated cells are also capable of destroying human fibroblasts in vitro (39) . In a number of diseases in which immune deficiency is present an impairment in PHA stimulation of lymphocytes has been reported (for references, see 12). Thus it is reasonable to assume that impaired in vitro lymphocyte stimulation in patients with Down's syndrome reflects an impairment in cellular defenses which could contribute to their enhanced vulnerability to pathogens.
In other studies we have shown a high incidence of Australia antigen, a particle of 200 A in diameter, associated with chronic anicteric hepatitis in institutionalized patients with Down's syndrome (4 
